Why work with us

Our deep knowledge and experience within OA is what makes NBCD stand out from the crowd

NBCD is a full-service CRO specialized in osteoarthritis, and we have conducted numerous OA trials in all clinical phases. We are dedicated to developing drugs for treatment of OA and specialize in trial design and execution of clinical trials within both OA pain and DMOAD compounds.

We are experts in placebo response mitigation and selecting the right patients for our partners and our legacy from Nordic Bioscience means that we have great experience with precision medicine using unique biomarker technologies to enhance drug development at all stages.

During the past 15 years, NBCD has successfully managed all aspects of several phase I, II and III trials within musculoskeletal conditions including  osteoarthritis, osteoporosis, and rheumatoid arthritis. In total, more than 15,000 subjects have been enrolled in our trials worldwide.

We have been successfully inspected by FDA, EMA and other national European agencies, and we have taken part of and led large clinical projects to FDA approvals. Recent examples include the pivotal phase 3 program of Zilretta® for OA pain and the pivotal phase 3 program of abaloparatide for osteoporosis. 

Our core competencies are:

  • Extensive experience on an operational as well as a scientific level
  • Staff with a scientific background and hence a clear understanding of the clinical science we perform. Our team is highly motivated, and our employee turnover rates are among the lowest in the industry.
  • Global reach with a network of high-enrolling, high-quality, dedicated clinical trial sites, which have proven able to rapidly recruit using a small number of sites
  • We have pioneered in applying Risk-Based Monitoring and Protocol Design strategies, with proven positive impact on data quality and cost-efficiency.
  • A unique intelligent feasibility approach, FeasIntel™, that harness the power of our proprietary clinical trial database to identify and emulate the most suitable population and sites for new OA trials